Literature DB >> 11913903

Central retinal vein occlusion and thrombophilia.

C D Fegan1.   

Abstract

Central retinal vein occlusion is one of the commonest vascular diseases of the eye. The pathogenesis is multifactorial with both local factors and systemic diseases being aetiologically important. Many thrombophilic conditions have recently been identified and studies looking at their potential role in CRVO have been undertaken. The aim of this review is to critically appraise these studies as to date many have given conflicting results, making it far from clear what role thrombophilic conditions play in CRVO. It appears that hyperhomocysteinaemia and antiphospholipid syndrome are causes of CRVO and there is evidence that disorders causing hypofibrinolysis may also be important. The common hereditary thrombophilic conditions however do not appear to be strong risk factors but larger studies are needed for a definitive answer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11913903     DOI: 10.1038/sj.eye.6700040

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  17 in total

1.  Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion.

Authors:  Hai-Yan Wang; Xiao Li; Yus-Sheng Wang; Zi-Feng Zhang; Man-Hong Li; Xiao-Na Su; Jin-Ting Zhu
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

2.  Retinal vascular occlusions: an interdisciplinary challenge.

Authors:  Alireza Mirshahi; Nicolas Feltgen; Lutz L Hansen; Lars-Olof Hattenbach
Journal:  Dtsch Arztebl Int       Date:  2008-06-27       Impact factor: 5.594

3.  Trombophilic screening for nonarteritic anterior ischemic optic neuropathy.

Authors:  Valeria Nagy; Zita Steiber; Lili Takacs; Gyorgy Vereb; Andras Berta; Zsuzsanna Bereczky; Gyorgy Pfliegler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-04-15       Impact factor: 3.117

4.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

5.  Retinal vein occlusion: pathophysiology and treatment options.

Authors:  Niral Karia
Journal:  Clin Ophthalmol       Date:  2010-07-30

6.  NONICHEMIC CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH HEREDITARY THROMBOPHYLIA.

Authors:  Andreea Dana Fişuş; Doina Suzana Pop; Monica Blanka Rusu; Florina Vultur; Karin Ursula Horvath
Journal:  Rom J Ophthalmol       Date:  2015 Jul-Sep

7.  [Retinal vein branch occlusion and palsy of the N. abducens in protein S deficiency].

Authors:  H M Holak; N H Holak; S Holak; S A Holak; S Szymaniec
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

8.  Venous thromboembolism does not share familial susceptibility with retinal vascular occlusion or glaucoma: a nationwide family study.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

9.  A longitudinal analysis of risk factors associated with central retinal vein occlusion.

Authors:  Maxwell S Stem; Nidhi Talwar; Grant M Comer; Joshua D Stein
Journal:  Ophthalmology       Date:  2012-11-20       Impact factor: 12.079

10.  Methylenetetrahydrofolate reductase C677T mutation and risk of retinal vein thrombosis.

Authors:  Mohammad Soleiman Soltanpour; Zahra Soheili; Ali Shakerizadeh; Ali Akbar Pourfathollah; Shahram Samiei; Reza Meshkani; Mohammad Shahjahani; Abbas Karimi
Journal:  J Res Med Sci       Date:  2013-06       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.